Opus Genetics, Inc (IRD)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Opus Genetics, Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Opus Genetics, Inc (IRD) has returned 126.37% so far this year and 363.43% over the past 12 months. Over the last ten years, IRD has returned -29.92% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since May 23, 2005, IRD's average daily return is +0.12%, while the average monthly return is +0.61%. At this rate, your investment would double in approximately 9.5 years.

Historically, 41% of months were positive and 59% were negative. The best month was Jan 2014 with a return of +125.5%, while the worst month was Aug 2019 at -57.2%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 8 months.

On a daily basis, IRD closed higher 40% of trading days. The best single day was May 12, 2009 with a return of +111.6%, while the worst single day was Apr 13, 2010 at -51.8%.

Opus Genetics, Inc has an annualized alpha of 21.20%, beta of 1.08, and R² of 0.04 versus S&P 500 Index. Calculated based on daily prices since May 24, 2005.

• This stock participated in 136.84% of S&P 500 Index downside but only -10.31% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.04 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

IRD ranks 98 for risk / return — in the top 98% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Opus Genetics, Inc (IRD) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Opus Genetics, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Opus Genetics, Inc was 99.98%, occurring on Apr 11, 2025. The portfolio has not yet recovered.

The current Opus Genetics, Inc drawdown is 99.84%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Opus Genetics, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Opus Genetics, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.